RESULT OF RIKSBANK CERTIFICATE SALE
|Interest rate, %||0.00|
|Offered volume, SEK bn||380.0|
|Total bid amount, SEK bn||1831.27|
|Accepted volume, SEK bn||380.0|
|Number of bids||15|
|Percentage alloted, %||20.751|
ISIN:To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Volta Finance Limited - Net Asset Value as at 30 April 202112.5.2021 18:17:42 CEST | Press release
Volta Finance Limited (VTA / VTAS) –April2021 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 12May2021 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for April. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY Volta has continued to perform well with +2.1% in April, reaching a total return of 8.4% for the first four months of 2021. In April, Volta paid €0.14 per share dividend to shareholders (circa 8% annualized yield), a €0.02 increase relative to the January dividend payment, evidencing the improving situation of Volta. This time around, the performance was driven almost evenly by the solid performance from CLO equity and CLO debt tranches. This month, contrary to March, the USD depreciation cost almost 1% of the monthly performance. The monthly
Idorsia holds its Annual General Meeting of Shareholders12.5.2021 18:09:53 CEST | Press release
Allschwil, Switzerland – May12, 2021 All Board proposals approved by the Shareholders At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Allschwil, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with a large majority. The meeting was held in accordance with the requirements of the COVID‑19 Ordinance 3, issued by the Swiss Federal Council. As a result, attendance in person was not possible and voting took place by independent proxy. In total, 4,541 shareholders voted through the independent proxy, representing a total of 112,170,657 shares, or 67.13% of the total outstanding shares. Mathieu Simon, MD, Chairman of the Board of Directors of Idorsia, commented: “Despite the global pandemic, Idorsia looks back on an incredibly successful year and the future promises to not lose any momentum. The coming year will be crucial as we continue to build the foundation of Idorsia's future. I am very proud to have been re-elected as your C
All resolutions adopted at AGM Beter Bed Holding N.V.12.5.2021 18:00:00 CEST | Press release
Beter Bed Holding N.V. (BBH) – a sleep specialist operating in the European retail, wholesale and B2B sectors – held its 2021 Annual General Meeting (AGM) in virtual form today. BBH is pleased to announce that all resolutions including the 2020 financial statements were adopted as proposed. When the resolutions were voted on, 11,577,389shares were represented, corresponding to 44.12 % of the 26,240,397 shares issued. The details of the voting results can be found atwww.beterbedholding.com. During the AGM, John Kruijssen, CEO, and Gabrielle Reijnen, CFO, also presented the strategic direction going forward, inspired by major global trends which will shape the future of the bedding industry. A separate press release on the strategy update was published this morning. The AGM presentation as well as the analyst presentation regarding the strategy update can be found on the BBH website at www.beterbedholding.com. About Beter Bed Holding Beter Bed Holding N.V. is a sleep specialist operating
OPENING OF NEW BRANCH OFFICE IN PARIS12.5.2021 17:45:00 CEST | Press release
OPENING OF NEW BRANCH OFFICE IN PARIS Amsterdam, the Netherlands – 12May 2021. Flow Traders N.V. (“Flow Traders”) announces the opening of new branch office in Paris, France. Today, Flow Traders announces the opening of a new branch office in Paris. The opening of this new branch office is consistent with Flow Traders’ growth strategy to deepen its global footprint and it will enable Flow Traders to have a physical presence in another key EMEA market. This office, alongside those in Amsterdam, London and Milan, will together cover the EMEA region for Flow Traders. Flow Traders’ day-to-day operations in Paris will be headed by Pierre-Antoine Jaunatre. The branch office will report directly into Flow Traders B.V.’s Amsterdam office. Ron Heydenrijk, European Head of Sales and External Relations, stated: “Following the successful opening of our London and Milan branches in 2018 and 2020, we are extremely pleased to be opening a third European branch office in Paris. Flow Traders’ continued
Immunicum håller presentationer vid European Hematology Association (EHA) 2021 Virtual Congress12.5.2021 16:02:34 CEST | Pressemelding
Pressrelease 12 maj 2021 Immunicum håller presentationer vid European Hematology Association (EHA) 2021 Virtual Congress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att hålla två posterpresentationer gällande sitt lagringsbara återfallsvaccin DCP-001 vid EHA 2021 Virtual Congress, som hålls den 9–17 juni 2021. Sammanfattningarna publiceras på konferensens webbplats och är även tillgängliga via www.ehaweb.org. Presentationerna innehåller interimsresultat från fas II ADVANCE II-studien, som visar DCP-001: s förmåga att inducera immunsvar mot ett brett spektrum av tumörassocierade antigener hos patienter med akut myeloisk leukemi (AML), samt prekliniska resultat av förbättrad effekt vid kombinationen DCP-001 och etablerade AML-behandlingar. "De kliniska interimsresultat som publiceras i sammanfattningen idag gläder oss i och med att vi ser att DCP-001 inducerar en rad detekterbara immunsvar hos AML-patienter som deltar i den pågående ADVANCE II-studien", säger Jeroen
Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress12.5.2021 16:02:34 CEST | Press release
Press Release 12 May 2021 Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress Immunicum AB (publ; IMMU.ST) today announced that it will be presenting two posters on its off-the-shelf relapse vaccine DCP-001 at the EHA 2021 Virtual Congress, to be held from June 9-17, 2021. The accepted abstracts are now published on the conference website and accessible through www.ehaweb.org. The presentations include interim immunological results from the Phase II ADVANCE II study, demonstrating DCP-001’s ability to induce immune responses to a broad range of tumor-associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-001 with established AML treatment regimens. “From the interim clinical data published in the abstract today, we are excited to see that DCP-001 induces a range of detectable immune responses in AML patients participating in our ongoing ADVANCE II study,” said
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress12.5.2021 16:00:00 CEST | Press release
New Oxbryta® (voxelotor) Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that six abstracts related to its sickle cell disease (SCD) programs will be presented at the European Hematology Association (EHA) 2021 Virtual Congress, taking place online June 9-17, 2021. Results from an analysis of the Phase 2a HOPE-KIDS 1 Study (GBT440-007) in children with SCD ages 4 to 11 years treated with Oxbryta® (voxelotor) tablets will be presented for the first time in an oral session. The HOPE-KIDS 1 analysis, which evaluated 45 children treated with Oxbryta (1,500 mg or weight-based equivalent), found that 47 percent achieved a hemoglobin increase of >1 g/dL at 24 weeks. Reductions in markers of hemolysis were also observed. Oxbryta was well tolerated, and no new adverse safe